These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32233322)

  • 41. Cell clonality in hypereosinophilic syndrome: what pathogenetic role?
    Galimberti S; Ciabatti E; Ottimo F; Rossi A; Trombi L; Carulli G; Cervetti G; Matti L; Bianchi G; Petrini M
    Clin Exp Rheumatol; 2007; 25(1):17-22. PubMed ID: 17417985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
    La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
    Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current differential diagnosis of hypereosinophilic syndrome].
    Dinić-Uzurov V; Lalosević V; Milosević I; Urosević I; Lalosević D; Popović S
    Med Pregl; 2007; 60(11-12):581-6. PubMed ID: 18666600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.
    Stein ML; Rothenberg ME
    Expert Rev Clin Immunol; 2005 Nov; 1(4):633-44. PubMed ID: 20477604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity.
    Valent P; Degenfeld-Schonburg L; Sadovnik I; Horny HP; Arock M; Simon HU; Reiter A; Bochner BS
    Semin Immunopathol; 2021 Jun; 43(3):423-438. PubMed ID: 34052871
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review.
    Requena G; van den Bosch J; Akuthota P; Kovalszki A; Steinfeld J; Kwon N; Van Dyke MK
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2125-2134. PubMed ID: 35470096
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary eosinophilic disorders: a concise review.
    Pardanani A; Tefferi A
    Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypereosinophilic syndrome: approach to treatment in the era of precision medicine.
    Klion A
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):326-331. PubMed ID: 30504328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
    Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
    Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis of non-parasitic hypereosinophilia].
    Kahn JE; Girszyn N; Blétry O
    Presse Med; 2006 Jan; 35(1 Pt 2):144-52. PubMed ID: 16462679
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypereosinophilic syndrome and proliferative diseases.
    Ionescu MA; Wang L; Janin A
    Acta Dermatovenerol Croat; 2009; 17(4):323-30. PubMed ID: 20021987
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eosinophilia in Hematologic Disorders.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):439-52. PubMed ID: 26209894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypereosinophilic syndrome: an update.
    Wilkins HJ; Crane MM; Copeland K; Williams WV
    Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia].
    Chrobák L; Voglová J
    Vnitr Lek; 2005 Dec; 51(12):1385-93. PubMed ID: 16430106
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and Biological Markers in Hypereosinophilic Syndromes.
    Khoury P; Makiya M; Klion AD
    Front Med (Lausanne); 2017; 4():240. PubMed ID: 29312946
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Practical approach to hypereosinophilia].
    Roufosse F; Cogan E
    Rev Med Brux; 2008 Sep; 29(4):400-8. PubMed ID: 18949995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
    Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
    Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
    Tan D; Hwang W; Ng HJ; Goh YT; Tan P
    Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
    Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
    Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.